PT - JOURNAL ARTICLE AU - Yau, Kevin AU - Abe, Kento T. AU - Naimark, David AU - Oliver, Matthew J. AU - Perl, Jeffrey AU - Leis, Jerome A. AU - Bolotin, Shelly AU - Tran, Vanessa AU - Mullin, Sarah AU - Shadowitz, Ellen AU - Garnham-Takaoka, Julie AU - de Launay, Keelia Quinn AU - Takaoka, Alyson AU - Straus, Sharon E. AU - McGeer, Allison J. AU - Chan, Christopher T. AU - Colwill, Karen AU - Gingras, Anne-Claude AU - Hladunewich, Michelle A. TI - The Humoral Response to the BNT162b2 Vaccine in Hemodialysis Patients AID - 10.1101/2021.05.24.21257425 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.24.21257425 4099 - http://medrxiv.org/content/early/2021/05/27/2021.05.24.21257425.short 4100 - http://medrxiv.org/content/early/2021/05/27/2021.05.24.21257425.full AB - Importance Hemodialysis patients have an exceptionally high mortality from COVID-19 and this patient population often has a poor response to vaccinations. Randomized controlled trials for COVID-19 vaccines included few patients with kidney disease, therefore vaccine immunogenicity is uncertain in this population.Objective Evaluate the SARS-CoV-2 antibody response in chronic hemodialysis patients following one versus two doses of BNT162b2 COVID-19 vaccination compared to health care worker controls and convalescent serum.Design Prospective observational cohort study.Setting Single centre study in Toronto, Ontario, Canada.Participants 142 in-centre hemodialysis patients and 35 health care worker controls.Exposure BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.Main Outcomes and Measures SARS-CoV-2 IgG antibodies to the spike protein (anti-spike), receptor binding domain (anti-RBD), and nucleocapsid protein (anti-NP) were measured in 66 hemodialysis patients receiving one vaccine dose following a public health policy change, 76 patients receiving two vaccine doses, and 35 health care workers receiving two vaccine doses.Results Detectable anti-NP suggestive of natural SARS-CoV-2 infection was detected in 15/142 (11%) of patients at baseline while only three patients had prior RT-PCR confirmed COVID-19. Two additional patients contracted COVID-19 after receiving two doses of vaccine. In patients receiving a single BNT162b2 dose, seroconversion occurred in 53/66 (80%) for anti-spike and 35/66 (55%) for anti-RBD by 28 days post dose, but only 15/66 (23%) and 4/66 (6%), respectively attained a robust response as defined by reaching the median level of anti-spike and anti-RBD in convalescent serum from COVID-19 survivors. In patients receiving two doses of BNT162b2 vaccine, seroconversion occurred in 69/72 (96%) for anti-spike and 63/72 (88%) for anti-RBD by 2 weeks following the second dose while 52/72 (72%) and 43/76 (41%) reached the median convalescent serum level of anti-spike and anti-RBD, respectively. In contrast, 35/35 (100%) of health care workers exceeded the median level of anti-spike and anti-RBD found in convalescent serum 2-4 weeks after the second dose.Conclusions and Relevance This study confirms poor immunogenicity 28 days following a single dose of BNT162b2 vaccine in the hemodialysis population, supporting adherence to recommended vaccination schedules, and avoiding delay of the second dose in these at-risk individuals.Question What is the serologic response to the BNT162b2 COVID-19 vaccine in hemodialysis patients?Findings In this prospective observational study, humoral response was compared in 66 hemodialysis patients sampled 28 days after receipt of one dose of vaccine to 76 patients who received two doses of vaccine sampled 14 days after the second dose. Among those receiving one dose, 6% had anti-RBD response above the median level of convalescent serum versus 41% who received two doses.Meaning Given that hemodialysis patients exhibit a poor humoral response to a single dose of BNT162b2 vaccine, the second dose should not be delayed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe equipment used is housed in the Network Biology Collaborative Centre at the Lunenfeld-Tanenbaum Research Institute, a facility supported by Canada Foundation for Innovation funding, by the Ontarian Government, and by Genome Canada and Ontario Genomics (OGI-139). ACG is supported by the Canadian Institutes of Health Research (FDN 143301) and a Canada Research Chair, Tier 1, in Functional Proteomics. KTA is a recipient of an Ontario Graduate Scholarship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Sunnybrook Health Sciences Centre Research Ethics Board (REB #4814). Health worker data was obtained from the Wellness Hub initiative (#20-0339-E, Mount Sinai Hospital). Convalescent serum data were obtained from the Toronto Invasive Bacterial Diseases Network (REB studies #20-044 Unity Health, #02-0118-U/05-0016-C, Mount Sinai Hospital).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article (and its supplementary information files).